Education
About Us
Working with TipRanks
Follow Us
Achilles Therapeutics Plc (ACHL)
NASDAQ:ACHL
Total Valuation
Achilles Therapeutics has a market cap or net worth of $60.83M. The enterprise value is ―.
Market Cap$60.83M
Enterprise Value―
Share Statistics
Achilles Therapeutics has 41,088,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,088,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Achilles Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -51.21%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-51.21%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee0.00
Profits Per Employee-342.82K
Employee Count204
Asset Turnover0.00
Inventory Turnover4.73M
Valuation Ratios
The current PE Ratio of Achilles Therapeutics is -0.51. Achilles Therapeutics’s PEG ratio is 0.24.
PE Ratio-0.51
PS Ratio―
PB Ratio0.58
Price to Fair Value0.25
Price to FCF-1.93
Price to Operating Cash Flow-1.95
PEG Ratio0.24
Income Statement
In the last 12 months, Achilles Therapeutics had revenue of 0.00 and earned -69.67M in profits. Earnings per share was -1.74.
Revenue0.00
Gross Profit-4.73M
Operating Income-75.25M
Pretax Income-69.17M
Net Income-69.67M
EBITDA-70.44M
Earnings Per Share (EPS)-1.74
Cash Flow
In the last 12 months, operating cash flow was -30.66M and capital expenditures -801.63K, giving a free cash flow of -31.47M billion.
Operating Cash Flow-30.66M
Free Cash Flow-31.47M
Free Cash Flow per Share-0.77
Dividends & Yields
Achilles Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.82
52-Week Price Change59.14%
50-Day Moving Average1.33
200-Day Moving Average1.03
Relative Strength Index (RSI)74.97
Average Volume (3m)1.84M
Important Dates
Achilles Therapeutics upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 4, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Achilles Therapeutics as a current ratio of 8.57, with Debt / Equity ratio of 3.51%
Current Ratio8.57
Quick Ratio8.57
Debt to Market Cap0.00
Net Debt to EBITDA1.80
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Achilles Therapeutics has paid 491.00K in taxes.
Income Tax491.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Achilles Therapeutics EV to EBITDA ratio is 1.30, with an EV/FCF ratio of 1.84.
EV to Sales0.00
EV to EBITDA1.30
EV to Free Cash Flow1.84
EV to Operating Cash Flow1.89
Balance Sheet
Achilles Therapeutics has $95.11M in cash and marketable securities with $4.46M in debt, giving a net cash position of -$90.65M billion.
Cash & Marketable Securities$95.11M
Total Debt$4.46M
Net Cash-$90.65M
Net Cash Per Share-$2.21
Tangible Book Value Per Share$3.56
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Achilles Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―